FORM 8-K

Current report filing

Filing Date: **2013-01-14** | Period of Report: **2013-01-11**
SEC Accession No. 0001144204-13-002153

(HTML Version on secdatabase.com)

FILER

Arno Therapeutics, Inc
CIK:**1195116**| IRS No.: **522286452** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-52153** | Film No.: **13527600**
SIC: **2834** Pharmaceutical preparations

Mailing Address
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON NJ 08822

Business Address
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON NJ 08822
(862) 703-7175

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2013

ARNO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-52153	**52-2286452**
(Commission File Number)	(IRS Employer Identification No.)

200 Route 31 North, Suite 104
Flemington, NJ 08822
(Address of principal executive offices and Zip Code)

(862) 703-7170
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

On January 11, 2013, Arno Therapeutics, Inc. distributed a letter to its stockholders. A copy of the letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including that incorporated herein by reference, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including that incorporated herein by reference, shall not be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits.* The following exhibits are filed herewith.

Exhibit No.	Description
99.1	Letter to stockholders of Arno Therapeutics, Inc. dated January 11, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 14, 2013

Arno Therapeutics, Inc.

By: /s/ Glenn R. Mattes
Glenn R. Mattes
President and Chief Executive Officer

Exhibit Index

Exhibit No.	Description
99.1	Letter to stockholders of Arno Therapeutics, Inc. dated January 11, 2013.

Exhibit 99.1

January 11, 2013

[ADDRESS]

Dear [INVESTOR]:

I am writing to express my deep appreciation of your financial support and to give you an update on Arno's plans for the year ahead. We made great progress in 2012 advancing our two lead investigational cancer drugs, onapristone and AR-42, through preclinical and clinical studies – and as a result of our recent $15 million financing, we are now in a much stronger position to expand that effort this year.

The completed debt financing enables us to continue the important work we have undertaken to develop onapristone and a companion diagnostic. We recently reported results of preclinical studies in which cancer cells that express the activated form of the progesterone receptor responded to treatment with onapristone while cells that did not express the activated form of the progesterone receptor did not respond to onapristone treatment.
We also reported progress in developing techniques to identify activated progesterone receptors and enable a method for selecting patients who are most likely to respond to antiprogestins such as onapristone. This suggests we are moving closer to identifying a clinical biomarker that may determine which patients with breast, endometrial and other cancers respond best to treatment with onapristone. Much of this work will be presented at this year's American Society of Clinical Oncology annual meeting in June – a terrific opportunity to showcase our findings and raise awareness of the drug and our companion diagnostic program.

We plan to initiate preclinical pharmacokinetic studies with onapristone this quarter and begin Phase 1 clinical testing in the second quarter of 2013. We are also seeking a development partner for the onapristone companion diagnostic - which is an integral part of our clinical program for this drug candidate – and hope to complete that search by mid-year.

AR-42 has shown promising activity in preclinical studies as a treatment for a variety of tumor types, including meningioma and schwannoma of the central nervous system. The orphan-drug designations we received last year for AR-42 will not only increase the potential commercial value of this compound but also help accelerate its clinical development. We plan to report the results of our dose-finding Phase 1 study with AR-42 early this year and begin a Phase 2 study in patients with solid tumors later this quarter.

Your investment in our company is enabling us to advance these novel drug candidates. Thanks to your support, we now have the resources to expand preclinical and clinical testing of these compounds and focus on their most promising indications. I look forward to updating you on our progress in the year ahead.

Best wishes and Happy New Year,

/s/ Glenn Mattes
Glenn Mattes
President and CEO

Forward-Looking Statements: This letter contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the potential for onapristone to treat APR-positive cancers, the timing, progress and anticipated results of the clinical and regulatory development of onapristone, our ability to develop a companion diagnostic for onapristone, our ability to fund the development of onapristone to completion, as well as our strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and investors are cautioned not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in our Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Reports on Form 10-Q for the quarters ended June 30, 2012 and September 30, 2012. We are providing this information as of the date of

this press release and do not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.